The IFI27 Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1703 human lung squamous cell carcinoma line, engineered to disrupt the IFI27 gene. This polyclonal knockout pool offers a heterogeneous loss-of-function model suitable for interrogating the functional role of IFI27 in cancer biology and innate immunity. The CRISPR/Cas9-mediated gene disruption targets the endogenous IFI27 locus, enabling researchers to study phenotypic consequences without the need for single-cell cloning or isolation of monoclonal populations. The product provides a versatile tool for dissecting interferon-responsive pathways and apoptosis mechanisms in a clinically relevant lung cancer background.
NCI-H1703 is a well-characterized epithelial cell line established from a 54-year-old male smoker diagnosed with stage 1 squamous cell carcinoma of the lung. As a model for non-small cell lung cancer, these cells retain key features of squamous differentiation and are widely employed for investigating lung tumor biology, drug response, and signal transduction. The host cell background offers a physiologically relevant context for exploring how IFI27 contributes to cancer cell survival and death, particularly given the frequent dysregulation of apoptotic and interferon pathways in lung malignancies.
IFI27, also known as ISG12a, is a small interferon-alpha-inducible protein that localizes to the mitochondrial membrane and functions as a pro-apoptotic effector downstream of type I interferon signaling. Upon stimulation by interferons (IFNA, IFNB, IFNG), IFI27 expression is robustly induced through the JAK-STAT pathway, involving upstream regulators such as STAT1, STAT2, and IRF9, which assemble into the ISGF3 transcription factor complex. Once expressed, IFI27 interacts with mitochondrial membrane proteins and BCL2 family members, including BCL2 and BAX, leading to mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspases. Thus, IFI27 directly links interferon receptor activation (IFNAR1/IFNAR2) and associated kinases (JAK1, TYK2) to the intrinsic apoptotic machinery, serving as a critical mediator of interferon-dependent cell death and antiviral responses.
The knockout of IFI27 in the NCI-H1703 lung cancer model is particularly significant for dissecting the interplay between innate immune signaling and tumor cell apoptosis. Lung squamous cell carcinoma frequently exhibits aberrant interferon pathway activity and apoptotic resistance, and IFI27 may act as a tumor suppressor or a stress-response factor in this context. By disrupting IFI27, researchers can evaluate its contribution to interferon-induced cytotoxicity, mitochondrial dysfunction, and chemosensitivity. This polyclonal knockout population provides a robust system to assess the impact of IFI27 loss on cell viability, clonogenic growth, and response to immunomodulatory therapies, without the constraints of clonal variation.
Typical research applications include functional characterization of IFI27 in interferon-stimulated apoptosis using flow cytometry (Annexin V/PI staining) and caspase activity assays. The cells are suitable for investigating transcriptional changes via RNA-seq following interferon treatment, as well as for Western blot analysis of IFI27 and downstream effectors such as BAX and cytochrome c. RT-qPCR can validate target disruption and monitor expression of interferon-responsive genes. The model supports drug screening for agents that modulate the interferon-apoptosis axis and combinatorial studies with kinase inhibitors targeting JAK1 or TYK2. Additionally, cell viability assays (MTT) can assess the role of IFI27 in modulating sensitivity to chemotherapeutics or death receptor ligands. For additional details and ordering information, please contact Ascent Research.
